Your browser doesn't support javascript.
loading
Why not to interfere with LDL-cholesterol freefall and why not to talk badly about statins.
Vnitr Lek ; 64(12): 1169-1175, 2019.
Article en En | MEDLINE | ID: mdl-30704253
ABSTRACT
Thanks to new drugs and treatments it is now possible, and therefore also advisable, to achieve very low LDL-cholesterol levels. This is primarily the inhibition of the proproteinconvertase subtilisin kexin 9 and LDL apheresis. Despite these new procedures, they remain the main antagonist of atherosclerosis and atherogenic dyslipidemia of statins. Statins are the basis of treatment always. If they are not enough or if they actually cause uncontrollable difficulties, they can be supplemented or replaced by other medications or treatments that reduce values of LDL-cholesterol. Often, however, their full potential is not fully exploited, and there are still completely unjustified concerns about their frequent and dangerous undesirable effects. We did our best to discuss this topic in more detail in this article. Key words aggressive treatment - LDL-cholesterol - statins.
Asunto(s)
Palabras clave
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Eliminación de Componentes Sanguíneos / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Aterosclerosis / Dislipidemias / LDL-Colesterol Límite: Humans Idioma: En Revista: Vnitr Lek Año: 2019 Tipo del documento: Article
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Eliminación de Componentes Sanguíneos / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Aterosclerosis / Dislipidemias / LDL-Colesterol Límite: Humans Idioma: En Revista: Vnitr Lek Año: 2019 Tipo del documento: Article